A novel technology, mRNA has the potential to broaden treatment options for many diseases and disorders. As mRNA becomes a major focus of drug development, it is necessary to partner with a one-stop CDMO to eliminate the increased risk associated with multiple tech transfers, as well as the added time and cost. In this whitepaper, Esther Yoo, Head of Development Sales, offers insights on how Samsung has been exploring the possibilities of mRNA since before the pandemic and is now leveraging this expertise.
A novel technology, mRNA has the potential to broaden treatment options for many diseases and disorders. As mRNA becomes a major focus of drug development, it is necessary to partner with a one-stop CDMO to eliminate the increased risk associated with multiple tech transfers, as well as the added time and cost. In this whitepaper, Esther Yoo, Head of Development Sales, offers insights on how Samsung has been exploring the possibilities of mRNA since before the pandemic and is now leveraging this expertise.
- CDO
- CGMP
- ADC
- Bio Campus
- IR
- CMO